Fortress Biotech (FBIO) Revenue & Revenue Breakdown
Fortress Biotech Revenue Highlights
Latest Revenue (Y)
$59.66M
Latest Revenue (Q)
$13.03M
Main Segment (Y)
Qbrexza
Fortress Biotech Revenue by Period
Fortress Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $59.66M | -21.23% |
| 2022-12-31 | $75.74M | 10.11% |
| 2021-12-31 | $68.79M | 50.86% |
| 2020-12-31 | $45.60M | 24.49% |
| 2019-12-31 | $36.63M | 36.26% |
| 2018-12-31 | $26.88M | -85.67% |
| 2017-12-31 | $187.58M | 1038.25% |
| 2016-12-31 | $16.48M | 1809.62% |
| 2015-12-31 | $863.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | - |
Fortress Biotech generated $59.66M in revenue during NA 2023, up -21.23% compared to the previous quarter, and up 221.94% compared to the same period a year ago.
Fortress Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $13.03M | -34.67% |
| 2023-12-31 | $19.95M | -42.60% |
| 2023-09-30 | $34.75M | 99.88% |
| 2023-06-30 | $17.39M | 39.88% |
| 2023-03-31 | $12.43M | -24.23% |
| 2022-12-31 | $16.40M | -0.75% |
| 2022-09-30 | $16.53M | -12.49% |
| 2022-06-30 | $18.89M | -21.06% |
| 2022-03-31 | $23.93M | 30.91% |
| 2021-12-31 | $18.28M | -13.32% |
| 2021-09-30 | $21.09M | 18.17% |
| 2021-06-30 | $17.84M | 53.99% |
| 2021-03-31 | $11.59M | -15.72% |
| 2020-12-31 | $13.75M | 45.11% |
| 2020-09-30 | $9.47M | 0.19% |
| 2020-06-30 | $9.46M | -26.79% |
| 2020-03-31 | $12.92M | 16.06% |
| 2019-12-31 | $11.13M | 13.90% |
| 2019-09-30 | $9.77M | 5.64% |
| 2019-06-30 | $9.25M | 42.81% |
| 2019-03-31 | $6.48M | -104.15% |
| 2018-12-31 | $-156.07M | -345.03% |
| 2018-09-30 | $63.69M | -0.22% |
| 2018-06-30 | $63.83M | 15.17% |
| 2018-03-31 | $55.42M | 22.30% |
| 2017-12-31 | $45.32M | -3.34% |
| 2017-09-30 | $46.89M | -7.52% |
| 2017-06-30 | $50.70M | 13.46% |
| 2017-03-31 | $44.68M | 254.20% |
| 2016-12-31 | $12.62M | 1193.85% |
| 2016-09-30 | $975.00K | -56.28% |
| 2016-06-30 | $2.23M | 237.88% |
| 2016-03-31 | $660.00K | 95.27% |
| 2015-12-31 | $338.00K | 1252.00% |
| 2015-09-30 | $25.00K | 100.00% |
| 2015-06-30 | - | -100.00% |
| 2015-03-31 | $500.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | - |
Fortress Biotech generated $13.03M in revenue during Q1 2024, up -34.67% compared to the previous quarter, and up 79.43% compared to the same period a year ago.
Fortress Biotech Revenue Breakdown
Fortress Biotech Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Zilxi | $1.96M | $2.27M | - | - | - |
| Accutane | $20.17M | $18.37M | $10.05M | - | - |
| Amzeeq | $6.20M | $7.24M | - | - | - |
| Exelderm | $2.40M | $3.46M | $5.36M | - | - |
| Qbrexza | $25.41M | $26.71M | $17.06M | - | - |
| Targadox | $3.20M | $7.97M | $22.38M | $28.07M | - |
| Ximino | $287.00K | $4.96M | $8.25M | $3.60M | - |
| Other Branded Revenue | - | - | $37.00K | $6.85M | - |
| Pharmaceutical And Biotechnology Product Development | - | - | - | $1.07M | - |
| Dermatology Products Sales | - | - | - | $44.53M | - |
| Return Reserve | - | - | - | - | $2.90M |
| License And Service | - | - | - | - | $1.70M |
| Royalty | - | - | - | - | $100.00K |
Fortress Biotech's latest annual revenue breakdown by segment (product or service), as of Dec 23: Qbrexza (42.61%), Accutane (33.82%), Amzeeq (10.40%), Targadox (5.37%), Exelderm (4.02%), Zilxi (3.29%), and Ximino (0.48%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qbrexza | $6.84M | $5.02M | $21.32M | $4.09M | $6.96M | $6.26M | $6.11M | $7.38M | - | - | - | - | - | - | - | - | - | - | - | - |
| Accutane | $5.72M | $5.82M | $15.52M | $4.65M | $4.14M | $4.12M | $5.20M | $4.91M | - | - | - | - | - | - | - | - | - | - | - | - |
| Zilxi | $369.00K | $273.00K | $1.65M | $314.00K | $422.00K | $554.00K | $555.00K | $741.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Amzeeq | $1.21M | $755.00K | $5.01M | $1.19M | $1.35M | $1.16M | $1.26M | $3.47M | - | - | - | - | - | - | - | - | - | - | - | - |
| Ximino | - | - | - | $612.00K | $1.18M | $1.77M | $1.03M | $967.00K | $1.41M | $2.19M | - | - | - | - | - | - | - | - | - | - |
| Exelderm | - | - | $1.88M | $511.00K | $445.00K | $1.00M | $1.31M | $704.00K | $668.00K | - | - | - | - | - | - | - | - | - | - | - |
| Targadox | - | - | $2.41M | $793.00K | $1.41M | $1.17M | $2.76M | $2.63M | $8.53M | $6.61M | $7.23M | $5.70M | - | - | - | - | - | - | - | - |
| Other Branded Revenue | - | - | - | - | - | - | - | $1.00K | $6.48M | $22.00K | - | - | - | - | - | - | - | - | - | - |
| Dermatology Products Sales | - | - | - | - | - | - | - | - | $17.52M | $19.61M | $15.29M | $10.72M | $13.72M | $9.45M | $9.41M | $11.95M | - | - | - | - |
| Pharmaceutical and Biotechnology Product Development | - | - | - | - | - | - | - | - | $759.00K | - | - | - | - | - | - | - | - | - | - | - |
| Pharmaceutical And Biotechnology Product Development | - | - | - | - | - | - | - | - | - | $1.48M | $2.56M | $868.00K | $26.00K | $28.00K | $42.00K | $972.00K | - | - | - | - |
| Consolidated | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.47M | $9.46M | $12.92M | - | - | - | - |
Fortress Biotech's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Qbrexza (48.38%), Accutane (40.48%), Amzeeq (8.53%), and Zilxi (2.61%).
Fortress Biotech Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accutane | $4.65M | $4.14M | $4.12M | $5.20M | $4.91M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Exelderm | $511.00K | $445.00K | $1.00M | $1.31M | $704.00K | $668.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Qbrexza | $4.09M | $6.96M | $6.26M | $6.11M | $7.38M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Targadox | $793.00K | $1.41M | $1.17M | $2.76M | $2.63M | $8.53M | $6.61M | $7.23M | $5.70M | $5.04M | $4.32M | $6.36M | - | - | - | - | - | - | - | - |
| Ximino | $612.00K | $1.18M | $1.77M | $1.03M | $967.00K | $1.41M | $2.19M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Zilxi | $314.00K | $422.00K | $554.00K | $555.00K | $741.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Amzeeq | $1.19M | $1.35M | $1.16M | $1.26M | $3.47M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Branded Revenue | - | - | - | - | $1.00K | $6.48M | $22.00K | $968.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Dermatology Products Sales | - | - | - | - | - | $17.52M | $19.61M | $15.29M | $10.72M | $13.72M | $9.45M | $9.41M | $11.95M | - | - | - | - | - | - | - |
| Pharmaceutical and Biotechnology Product Development | - | - | - | - | - | $759.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pharmaceutical And Biotechnology Product Development | - | - | - | - | - | - | $1.48M | $2.56M | $868.00K | $26.00K | $28.00K | $42.00K | $972.00K | - | - | - | - | - | - | - |
| Consolidated | - | - | - | - | - | - | - | - | - | - | $9.47M | $9.46M | $12.92M | - | - | - | - | - | - | - |
| License and Service | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.10M | - | - |
| Other branded revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $846.00K | $326.00K |
Fortress Biotech's latest quarterly revenue breakdown by geography, as of Mar 23: Accutane (38.21%), Qbrexza (33.65%), Amzeeq (9.81%), Targadox (6.52%), Ximino (5.03%), Exelderm (4.20%), and Zilxi (2.58%).
Fortress Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals | $726.44M | $241.96M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| LUMO | Lumos Pharma | $2.05M | $488.00K |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| EYEN | Eyenovia | $3.79K | $4.99K |
| APTO | Aptose Biosciences | - | - |
| MBIO | Mustang Bio | - | - |
| CABA | Cabaletta Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| ALRN | Aileron Therapeutics | - | - |
| ATHA | Athira Pharma | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ACHL | Achilles Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| KOD | Kodiak Sciences | - | - |
| RNAZ | TransCode Therapeutics | - | - |
FBIO Revenue FAQ
What is Fortress Biotech’s yearly revenue?
Fortress Biotech's yearly revenue for 2023 was $59.66M, representing a decrease of -21.23% compared to 2022. The company's yearly revenue for 2022 was $75.74M, representing an increase of 10.11% compared to 2021. FBIO's yearly revenue for 2021 was $68.79M, representing an increase of 50.86% compared to 2020.
What is Fortress Biotech’s quarterly revenue?
Fortress Biotech's quarterly revenue for Q1 2024 was $13.03M, a -34.67% decrease from the previous quarter (Q4 2023), and a 4.84% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $19.95M, a -42.60% decrease from the previous quarter (Q3 2023), and a 21.59% increase year-over-year (Q4 2022). FBIO's quarterly revenue for Q3 2023 was $34.75M, a 99.88% increase from the previous quarter (Q2 2023), and a 110.26% increase year-over-year (Q3 2022).
What is Fortress Biotech’s revenue growth rate?
Fortress Biotech's revenue growth rate for the last 3 years (2021-2023) was -13.27%, and for the last 5 years (2019-2023) was 62.88%.
What are Fortress Biotech’s revenue streams?
Fortress Biotech's revenue streams in c 23 are Zilxi, Accutane, Amzeeq, Exelderm, Qbrexza, Targadox, and Ximino. Zilxi generated $1.96M in revenue, accounting 3.29% of the company's total revenue, down -13.68% year-over-year. Accutane generated $20.17M in revenue, accounting 33.82% of the company's total revenue, up 9.77% year-over-year. Amzeeq generated $6.2M in revenue, accounting 10.40% of the company's total revenue, down -14.37% year-over-year. Exelderm generated $2.4M in revenue, accounting 4.02% of the company's total revenue, down -30.84% year-over-year. Qbrexza generated $25.41M in revenue, accounting 42.61% of the company's total revenue, down -4.88% year-over-year. Targadox generated $3.2M in revenue, accounting 5.37% of the company's total revenue, down -59.81% year-over-year. Ximino generated $287K in revenue, accounting 0.48% of the company's total revenue, down -94.21% year-over-year.
What is Fortress Biotech’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Fortress Biotech was Qbrexza. This segment made a revenue of $25.41M, representing 42.61% of the company's total revenue.